<DOC>
	<DOCNO>NCT01732367</DOCNO>
	<brief_summary>This study provide rationale switch lamivudine plus adefovir tenofovir monotherapy Lamivudine plus Adefovir Treated Lamivudine-resistant chronic hepatitis B patient Undetectable Hepatitis B Virus DNA</brief_summary>
	<brief_title>TDF VS LAM + ADV LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA</brief_title>
	<detailed_description>Recently , Korea , long-term medication antiviral agent result resistance expression serious cause failure treat chronic hepatitis B. Exp . In particular , annual resistance rate lamivudine currently widely use Korea amount 15 20 percent rate expect reach 70 80 percent four five year . The guideline American Association Study Liver Disease ( AASLD ) European Association Study Liver ( EASL ) recommend combination therapy adefovir tenofovir patient lamivudine resistant HBV . In Korea , however , case combine prescription lamivudine adefovir , one cover health insurance therefore many patient difficult continue treatment due economic condition . Tenofovir develop recently place sale sooner later Korea strong antiviral effect , cause little emergence resistant virus , know low nephrotoxicity adefovir . In particular , several paper report tenofovir effective sustain antiviral effect patient antiviral agent resistant HBV well receive initial treatment . This show patient lamivudine resistant HBV treat tenofovir without combination therapy low level HBV DNA , treatment relatively effective despite resistance adefovir . Therefore , consider tenofovir switch therapy patient undetectable HBV DNA lamivudine plus adefovir combination therapy maintain virus response . The result study provide rationale switch lamivudine plus adefovir tenofovir monotherapy patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male female patient age 18 old The CHB patient ( HBeAgpositive negative ) least 6 month undetectable HBV DNA ( serum HBV DNA ≤ 20 IU/mL ) lamivudine plus adefovir combination therapy . Patients decompensated liver disease Patients HCV , HDV HIV Patients HCC Serum ALT &gt; 2x ULN level Serum creatinine &gt; 2.0mg/dL Pregnant lactate woman Women plan pregnancy within three come year Patients uncontrolled severe concomitant diseases— severe cardiovascular disease infection Those capability understand sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tenofovir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Adefovir</keyword>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>